www.theannals.com EDITORIAL T he practice of pharmacy continues to evolve as health care moves forward with new therapies in the quest to improve both the quality and quantity of life for patients. We live in an era when technology seems to advance at a faster and faster pace. Those charged with thoughtfully considering all of the ramifications of a proposed therapy find themselves constantly far behind the innovators who are pressing forward with the latest and greatest new device or drug. Patients and researchers are often impatient with those who challenge the propriety of what is being proposed. Others believe that "just because we can do it doesn't mean we should do it." Calling "time out" for thoughtful consideration, however, usually places individuals on the wrong side of the issue in the eyes of the popular media, which has its own self-interest in sensationalizing breakthrough therapies. Practicing pharmacists need help and guidance as they wrestle with the legal, ethical, and moral dilemmas associated with modern therapies.
Background
Plan B is currently marketed as a prescription-only product consisting of 2 tablets, each of which contains 0.75 mg of a single active steroid ingredient, levonorgestrel [18,19- Dinorpregn-4-en-20-yn-3-one-13-ethyl-17-hydroxy-, (17α)-(-)-]. Levonorgestrel is a totally synthetic progestogen. Plan B was approved for use in the US on July 28, 1999, 1 for the following indication: "Plan B is an emergency contraceptive [EC] that can be used to prevent pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the first tablet should be taken as soon as possible within 72 hours of intercourse. The second tablet should be taken 12 hours later." 2 The Food and Drug Administration (FDA) received a request from Women's Capital Corporation to switch Plan B from prescription to over-the-counter (OTC) status. On May 7, 2004 , the FDA issued a "Not Approvable" letter because the supplemental application, according to the FDA, did not meet the criteria for approval in that it did not demonstrate that Plan B could be used safely by adolescent girls for EC without the professional supervision of a licensed practitioner. The Non-Prescription Drug Advisory Committee and the Advisory Committee for Repro-ductive Health Drugs, during a joint session, had reviewed the application during the FDA's December 16, 2003, committee meetings and voted 23-4 to approve the switch from prescription to OTC status. The FDA is not bound by advisory committee votes, but it is rare for such a committee decision and vote to be overturned.
In the "Briefing Document" prepared for the December 16, 2003, meeting, Women's Capital Corporation (subsidiary of Duramed Pharmaceuticals, Inc., a subsidiary of Barr Laboratories, Inc.) contended that Plan B is an ideal candidate for switching because early use of Plan B strongly increases its efficacy, Plan B has an appropriate safety profile and a compelling risk/benefit assessment, and Plan B is not used chronically. 3 In March 2004, when Barr perhaps realized the potential of this application to fail, it proposed marketing Plan B as a prescription-only product for patients <16 years of age and as an OTC for those >16 years. 4 This proposed dual status was termed unprecedented by Steve Galson MD MPH, acting director of the FDA's Center for Drug Evaluation and Research. Galson indicated in the "not approvable" letter 5 to Barr Laboratories, Inc. the following reason for the denial:
"Based on a review of the data, we have concluded that you have not provided adequate data to support a conclusion that Plan B can be used safely by young adolescent women for emergency contraception without the professional supervision of a practitioner licensed by law to administer the drug. In your March 11, 2004 , amendment, you proposed to change the indication to allow for marketing of Plan B as a prescription-only product for women under 16 years of age and a nonprescription product for women 16 years and older. This preliminary proposal did not include draft product labeling to demonstrate how you propose to comply with both the prescription and nonprescription labeling requirements in a single packaging configuration. Because of the preliminary and incomplete nature of the proposal, we did not conduct a complete review of this amendment during this review cycle. "Before this application can be approved, you would have to provide data demonstrating that Plan B can be used safely by women under 16 years of age without the professional supervision of a practitioner licensed by law to administer the drug. Alternatively, you could supply additional information in support of the revised indication to allow for marketing of Plan B as a prescription-only product for women under the age of 16 years and a nonprescription product for women 16 years and older, including draft product labeling. If you take the latter approach, your response to this letter would have to include details of how you propose to implement simultaneous prescription and nonprescription marketing of Plan B for women of different ages in a single packaging configuration while complying with all relevant statutory and regulatory requirements for labeling and marketing of this product. We will have to assure ourselves that your proposed approach is consistent with our statutory authority. If you pursue the alternative approach, we also would request details of your proposed program to educate consumers, pharmacists, and physicians about the dual marketing of Plan B as both a prescription and nonprescription product, as well as your proposed program to monitor implementation of this novel approach." Depending upon one's point of view, this letter from the acting director has been very controversial.
The mechanism of action of levonorgestrel as EC appears to result primarily from an inhibition or delay of ovulation. Studies reviewed by various authors indicate that the mechanism of action of levonorgestrel does not appear to involve preventing pregnancy by interference with the implantation of fertilized eggs. 6 The Practice Committee of the American Society for Reproductive Medicine states that: "…effectiveness appears to result primarily from an inhibition or delay of ovulation and neither appears to interrupt or disrupt an already established pregnancy." Elsewhere, it is noted that the suggestion that EC alters endometrial receptivity or impedes implantation has not been supported, and there is no evidence of teratogenic effects. 7, 8 The regulatory controversy surrounding the use of Plan B as EC is matched by the professional, religious, and societal milieus surrounding EC. Grimes et al. 9 indicate "that prescription status for EC poses an unnecessary barrier to prompt effective use of this preventive therapy." Rudd 10 has stated: "Uncontrolled availability of Plan B is certain to lead to more high-risk sexual activity, resulting in more damaging STDs-damaging to body and soul." The controversy has thus been discussed in the medical and pharmacy literatures from varying points of view.
Some concerns over the use and outcomes of EC have revolved to a great degree around use and purposes, and outcomes of use relative to unwanted pregnancies and/or avoiding abortions. Trussell et al. 11 note that there are concerns that women who use EC may become lax with their regular birth control methods; however, reported evidence indicates that making EC more readily available would ultimately reduce the incidence of unintended pregnancies. Farrar et al. 12 note that post-coital contraception could reduce the number of unintended pregnancies by 2 million and the number of induced abortions by 1 million.
EC has been available in the UK since 1984 on a prescription basis. In an experimental and control trial studying EC, the authors concluded: "Making emergency contraception more easily attainable does no harm and may reduce the rate of unwanted pregnancies." 13 Women in this British study did not abandon more reliable methods of birth control in favor of EC.
Raine et al. 14 and Gold et al. 15 found that providing advance EC to adolescents was not associated with more unprotected intercourse or less condom or hormonal contraception use. The Gold et al. study included 301 predominantly minority patients who were 15-20 years of age.
This controversy will no doubt intensify in the future. The British journal The Lancet has weighed in on this issue with a highly critical commentary about the recent actions of the FDA on this and other issues. 16 The purpose of this editorial is to provide a thoughtful interchange of the various points of view that accompany EC and its status as an OTC or a prescription-only product. All members of the Medicine, Law, and Ethics panel of The Annals' editorial board were canvassed to assess their views on this issue.
Dr. Warren Richards: The first dilemma pharmacists face when dispensing EC will depend on the mechanism of action of the drug. If EC simply prevents conception, few would oppose it. If, on the other hand, EC interferes with implantation after conception, some may consider it simply a "chemical abortion" and oppose it for personal moral or ethical reasons. I, personally, would probably fall into the latter category if the mechanism of action is to simply block the implantation of a fertilized egg.
A second dilemma stems from the OTC status proposed for the drug. OTC status clearly makes it possible to remove parents from the decision process regarding their minor children. Again, many would oppose OTC status for this reason. I am not sure how I feel about that, except that the issue clearly points out the need for thorough counseling of patients by their pharmacist, regardless of prescription status. Patients will be self-medicating based on their own perception of need regardless of the circumstances surrounding their purchase of the drug. That means pharmacists must be proactive in providing clear and complete information about the use of the drug.
The current proposal for dual status-prescription only for patients <16 years old but OTC for those older-raises another interesting issue. Enforcing this proposal would probably place the drug behind the prescription counter as a third "class" of drug. While most pharmacists would view this as a recognition of their value in the healthcare system, some would see this as a requirement to participate in a process they believe to be immoral or unethical.
This then raises the issue of what, if anything, happens to the pharmacist who, for whatever reason, chooses not to participate in the distribution of this drug. Should licensing bodies sanction these pharmacists? Should employers discharge them? We have already seen pharmacists cited for following their conscience regarding this therapy. For me, this is a clear example of the need for conscience-clause protection for many of our pharmacist colleagues.
Dr. William E Fassett: This is a good example of how discussions of professional ethics often hinge on the underpinning facts. Many persons, including pharmacists, believe that Plan B's mechanism of action is to prevent implantation of a living being, thus causing its death; they equate this with abortion. This raises possibilities of pharmacists wishing to avoid participating in Plan B's distribution as a matter of conscience. If it is available OTC, these same pharmacists will not be forced to deal with it in a formal pharmacist-patient relationship, but may still wish to avoid working in an establishment that carries it. However, the OTC version may be more akin to condoms; some religions oppose their use and sale, as well, but this has not seriously affected their availability in the US. I think the major issue deals with how pharmacists discharge their obligations to distribute lawfully prescribed products to which they have an ethical objection. The harder the case (eg, euthanasia, abortion), the clearer the issues, but a discussion of conscientious objection would cover similar principles in any case.
We must begin by presuming that pharmacists, by taking on the mantle of health professionals, have a duty to provide care to patients, and that patient preferences and needs must be their first consideration, overriding the preferences of pharmacists. The notion that pharmacists have a "right to refuse to dispense any prescription" is a canard; in my view, health professionals have no special rights as professionals, but only the same rights enjoyed by all citizens. A right to refuse to dispense implies that such refusal can be exercised without explanation or reason. It is more correct to say that, in many cases, a pharmacist has a responsibility to decline a request for a drug, either in the patient's best interest or because the law forbids it under the circumstances. As a citizen, the pharmacist certainly has a right to refuse to engage in illegal activity and to avoid being drawn into a position of liability for harm to the patient.
Subsequent to the Nürnberg trials of Nazi officials at the end of World War II, it has been a recognized tenet of international law that citizens have a duty to refuse to follow otherwise lawful orders of their government that would constitute crimes against humanity. Because the US government was a chief proponent of this philosophy during the Nürnberg trials, it certainly seems that this society should honor the conscientious objections of its citizens to performing otherwise lawful acts when the objection is a matter of deeply, consistently, and authentically held moral commitments. However, we have uniformly required that conscientious objection meet the tests of publicity and authenticity.
Publicity, as it applies to healthcare providers, requires that patients be informed before entering into the relationship with their provider whether the provider will refuse to provide certain kinds of lawful care. Patients seeking care need to know how far the provider will go to aid them in dealing with risks to their life or health. The Centers for Disease Control and Prevention report that 43% of pregnant women experience morbidity during pregnancy, 17 and about 12 pregnant women die during pregnancy for every 100 000 live births 18 (thus, it is many times safer to fly than to get pregnant, 19 and there is about an equal chance that a woman will die during a given pregnancy as she will die while riding in a car during a given year 20 ). A pregnant woman is entitled to know if her obstetrician is unwilling to perform an abortion even if it would be medically necessary to save her life. Likewise, a pharmacist whose practice provides care for women of child-bearing age ought to be forthright in advising his or her patients whether he or she will not provide EC necessary to prevent the patient from being unwillingly exposed to the risks of pregnancy.
Authenticity is a formal requirement for granting conscientious objector status to those who refuse military service that might require them to kill a human being. The government requires evidence of a long-standing objection to taking a life in times of war and documentation that this is as a result of a deeply held moral conviction. While these formal requirements are not suggested by any of the proponents of a conscience clause for health providers, and indeed is not a factor in various state abortion laws that protect providers from being forced to participate, it is a personal moral requirement that should be met by each objecting provider. The ethical pharmacist must exercise careful introspection into his or her beliefs and ensure that these beliefs are authentically rooted in a consistently applied system of moral convictions and actions. Mere "moral squeamishness" is insufficient to override a duty to provide lawful care to patients.
In my view, given the evidence that Plan B's mechanism of action is prevention of ovulation and lack of evidence that it works by preventing implantation, a knowledgeable pharmacist cannot actually conclude that dispensing Plan B is a means of taking human life. We presume that the patient is entitled to receive any lawful drug; the burden of proof that dispensing Plan B actually violates the pharmacist's core objection to taking human life is on the pharmacist, and it is unethical to base such a refusal to provide care on supposition or vague generalizations repeated in the popular literature.
Many pharmacists raise objections to the wide availability of contraception and EC on the grounds that it encourages adolescents to have sex. Although well-controlled studies have demonstrated this to be an unproven belief, it is, of course, a public policy matter on which all citizens are entitled to express an opinion. However, this public policy concern cannot justify refusing to provide this lawful treatment to an individual patient when the need arises.
Should Plan B eventually be available OTC, it is worth noting that the US Supreme Court has struck down laws that prohibit minors from obtaining nonprescription contraceptives 21 and that most states specifically allow minors aged ≥13 years to consent to medical care for reproductive health and sexually transmitted diseases, without requiring parental consent. As with condoms, OTC Plan B would be lawfully available to minors. Evidence from studies in Europe and elsewhere does not support concerns about increased sexual activity when minors have EC available to them in advance of need, nor does it support any concerns about minors frequently using EC in lieu of other forms of contraception.
While I do recognize the responsibility of individuals to act in accordance with their moral compass-and applaud our moral leaders who act with the courage of their convictions-I cannot conclude that pharmacists are justified when they refuse to dispense Plan B or to carry it for OTC sale, even if they have moral convictions that would preclude them from participating in abortions.
Dr. Curtis E Harris: I see this as a classic debate between disciplines. That is, in their proper roles, the scientist asks "can we?", the lawyer asks "may we?", and the ethicist asks "should we?" The scientist both confuses his role and steps outside his expertise when he asks and answers the questions "may we?" and "should we?" To a significant degree, Dr. Fassett has gone beyond his area of expertise when he discusses both the law and the ethical obligations of medical professionals, at least as these differing areas apply to the OTC use of Plan B.
First, it is important to remember that technology is never value-neutral. Any medical advance that is considered worthwhile starts with the question "how will this make things better?" "Good," "better," and "best" are valuesladen terms, subject to broad individual and social interpretation. Plan B is no exception. Dr. Fassett recognizes this idea when he argues from the literature that pregnancy is itself a human condition associated with both morbidity and mortality: "it is many times safer to fly than to get pregnant," where "safer" implies (for Dr. Fassett) "better" for some women. I would argue that, if we were all to merely fly, rather than reproduce, such "safer" behavior would rapidly endanger all human survival, even that of the fertile woman who merely chooses to fly. Thus, it is the moral framework of the question asked that determines the impact of any new use of medical technology.
Second, as a society, we have agreed that some medical interventions can never be "good." Uninformed experimentation on nonconsenting competent adults is one example. Other interventions are always "good." Necessary CPR at an accident scene is one example. It is in the area between the extremes, where society has not decided the moral weight of a medical intervention, that human judgment and moral freedom are normally given greatest latitude.
Third, when a medical intervention directly impacts the highly contentious, values-laden area of human reproduction, all 3 disciplines (science, law, ethics) have recognized the equal moral positions of both the healthcare provider and the patient. When the US Supreme Court overturned state laws in Connecticut and Rhode Island prohibiting sale of OTC condoms and prescription contraceptives to married and unmarried individuals (see Griswold v Connecticut [1965] 22 and Eisenstadt v Baird [1972] 23 ), the Court explicitly stated that an individual healthcare provider could refuse to prescribe or provide contraception to any person, based on the professional's "conscience." Further, the refusal was not subject to state review any more than was the patient's right to receive contraceptives. Thus, the "right of conscience" was not subject to a formal inquiry as to the religious convictions of the provider, as might be undertaken in the example of a conscientious objector for military service. As far as constitutional law is concerned, a healthcare provider may, without explanation or reason, refuse a patient's request for a contraceptive. (Of note, this "right of conscience" for healthcare providers was also recognized in Roe v Wade [1973] , 24 the decision that legalized abortion in the US, and reiterated by incorporation once again in Planned Parenthood v Casey [1992] 25 ). Despite these decisions, organizations dedicated to the unrestricted access of women to all reproductive services, including abortion and sterilization, have begun to press the courts to force hospitals and physicians to provide such services, under the principle that federal funding of hospitals through Medicare and Medicaid mandate such care. Congress has responded by passing legislation through the House of Representatives that would prohibit such suits (The Healthcare Right of Conscience Act). The Senate has, as of this writing, not considered the bill.
Fourth, at the state law level, the most important privilege enjoyed by all healthcare providers is the right to refuse care to any individual seeking that care, or more precisely, the "No Duty to Treat" principle. 26 Consistent decisions over the last 100 years by the various Supreme Courts in state after state have determined that there is no legal right to health care in the US. The single most impor-tant exception to this privilege is the federal EMTALA (Emergency Medical Treatment and Labor Act) statute, which requires hospitals and emergency departments to stabilize a patient before transfer to another facility. The importance of EMTALA in this discussion is the clear recognition of Congress that, short of the statute, a hospital, clinic, or physician had no legal duty to treat someone before transferring him or her to the care of another. Thus, a healthcare provider has no legal obligation to provide any medication or treatment to any person merely because that person requests it.
Finally, recognizing the position of the law above, if a pharmacist has any duty to any patient to provide any form of treatment, such a duty must arise from tort law, contract law, or some ethical duty of the profession. Tort law would apply primarily to competence, contract law would apply primarily to the business of pharmacy, and ethical duties are established by the profession for guidance of behavior, but would have some legal impact in licensure review proceedings. Without discussing each in detail, and considering these 3 areas of law as they apply to the provision of OTC Plan B by a pharmacist, it is possible to conclude that tort law would be invoked only in cases of professional abandonment or incompetence; contract law would apply to agreements with other providers or insurance companies, and to certain provisions in an employment agreement; and ethical duties have little force based on the uncertain safety, mechanism of action, and overriding personal freedoms granted to the individual pharmacist.
Despite the few reassuring studies quoted by Dr. Fincham in the introduction and background sections, none of the studies applies to the questionable use of OTC Plan B on demand and without prescription by women of all ages. All of the studies to date have been conducted under the care of a physician, have not been controlled or prospective, have not addressed the issue of overuse or incorrect use of OTC Plan B, and have not examined the social behavior of adolescents who use OTC Plan B.
Based on the information at hand, it is equally possible for me to conclude that OTC Plan B is a hazard to a patient, rather than a benefit. It is also possible for me to conclude, based on the known chemistry of the drug, that in some circumstances, such as late use or repeated use after intercourse, OTC Plan B would cause a miscarriage or abortion. I simply cannot know enough from the available data to decide. Often, such as in the recent recall of Vioxx, safety and efficacy data are available years after all of the contrary reassurances of the FDA and others. Approval by the FDA does not protect a physician from being sued for the use of a drug, as evidenced by the Fen-Phen litigation. Recent case law has expanded the liability of a pharmacist in such instances. No one should be lulled into a position of "knowing the truth" about OTC Plan B.
Therefore, if I believe that OTC Plan B has unproven safety, could expose me to future liability, and might have an action I morally oppose, I have reached a logical, ethical, and internally consistent reason not to stock or sell OTC Plan B. Just as a pharmacy has no obligation to sell tobacco products (or even candy), a pharmacy has no obligation to sell OTC Plan B. Nothing in the law or professional ethics, other than the vague "duty of a citizen" cited by Dr. Fassett, compels any other conclusion.
Dr. Jack E Fincham: As can readily be discerned from the above thoughtful commentaries, views differ on the concept, mode of action, and acceptability of the Plan B EC. This issue has transcended the boundaries of the health and legal professions, healthcare system, and society. Participants in the recent debate regarding this issue and its ramifications have been critical of actions of pharmacists choosing to not fill prescriptions for ECs-in fact, bringing up the issue of obstruction versus objection. 27 The issues involved will become even more complex with the OTC availability (or lack thereof) of EC in the near future. This is one of many current and future dilemmas that will require contemplation and subsequent action rather than simple following of orders without prior thoughtful consideration.
